Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Glia. 2013 Jul 8;61(9):1456–1470. doi: 10.1002/glia.22534

Figure 4. Klk6, thrombin and PAR1-AP promote process retraction in Oli-neu oligodendrocytes.

Figure 4

A, Photomicrographs show retraction of Oli-neu oligodendrocyte processes 24 h after treatment with Klk6, thrombin or PAR1-AP, but not Klk1. B, Histograms show counts of Cy3-Phalloidin stained Oli-neu processes per cell after 24 h treatment with Klk6 (30, 150, 300 nM), thrombin (270 nM), PAR1-AP (100 μM) or Klk1 (300 nM). Klk6 caused a dose-dependent retraction of Oli-neu processes, relative to control (SNK, p = 1.5 × 10−4). Thrombin (SNK, p = 1.1 × 10−4) and PAR1-AP (SNK, p = 2.7 × 10−4), but not Klk1, also promoted significant process retraction. C, Histogram shows counts of Oli-neu cells per field in each treatment condition, presented as mean number of Phalloidin+ processes/DAPI+ nuclei. 30 nM Klk6 and PAR1-AP treatment resulted in a small but significant increase in Oli-neu cell number (SNK, p = 0.03 and p = 0.003, respectively). Error bars indicate SEM. * p < 0.05; ** p < 0.001, SNK. Scale bar = 100 μm.